 |
 |
|
 |
Advancing Therapeutics For Rare Diseases |
|
|
|
|
Advancing Therapeutics For Rare Diseases |
|
ChenodalTM 250 mg (chenodiol tablets) Approved By The FDA
We are pleased to announce that on October 22, 2009 The Food and Drug Administration (FDA) issued an approval for the Manchester Pharmaceuticals, Inc.™ version of chenodiol 250 mg tablets, which will be marketed in the United States under the trade name of Chenodal™.
A New Specialty Pharma Company Focused On Rare Diseases
Manchester Pharmaceuticals is an emerging specialty pharmaceutical company that is focused on the identification, development and commercialization of new therapeutic modalities to address the special needs of patients with rare diseases.
Manchester Pharmaceuticals has three products in various stages of development. The most advanced product, Chenodal, was recently approved by the FDA. Two other products are also under development; MP-120 and MP-135.
Manchester's founders and management together have extensive experience in successfully navigating the regulatory process in the US, having brought more than 15 products from development through to FDA approval in the past 10 years.
|